Results 91 to 100 of about 10,254 (215)

Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imaging

British Journal of Haematology, Volume 208, Issue 6, Page 2079-2086, June 2026.
Summary The Tackling Early Morbidity and Mortality in Myeloma trial (TEAMM) trial recruited 977 newly diagnosed myeloma patients from 93 UK hospitals to assess the advantages and disadvantages of prophylactic antibiotics for the first 12 weeks. This paper analyses the 133 (14%) patients who had previously known precursor disease including monoclonal ...
Aidan Haslam, Gulnaz Iqbal, Mark Drayson, Guy Pratt, Kwee Yong, Janet Dunn, Catherine Atkin, Chris Bunce, Donna Howe, Stella Bowcock   +9 more
wiley   +1 more source

Monoclonal gammopathy of “ocular” significance

American Journal of Ophthalmology Case Reports, 2019
Purpose: Diagnostic criteria for monoclonal gammopathy of undetermined significance (MGUS) do not currently include ocular phenotypic changes. Here, we offer a new diagnostic approach that is useful in patients with posteriorly located corneal ...
Sezen Karakus, John D. Gottsch, Patrizio Caturegli, Allen O. Eghrari   +3 more
doaj   +1 more source

Living kidney donor with monoclonal gammopathy of undetermined significance: Is it a contraindication for kidney donation?

, 2019
Kidney transplantation is the treatment of choice for patients suffering from end-stage renal disease. We report a case of living kidney transplantation in which the donor had monoclonal gammopathy of undetermined significance, a condition having ...
Vinay Rathore, Pankaj Beniwal, Dhananjai Agarwal, Sanjeev Sharma, Vinay Malhotra, Rajesh Jhorawat   +5 more
core   +1 more source

Tres casos de gammapatía monoclonal de significado renal postrasplante renal: nefropatía c3 de novo

Nefrología, 2019
Resumen: La gammapatía monoclonal de significado renal incluye todas las enfermedades renales causadas por una inmunoglobulina monoclonal secretada por un clon de célula B no maligno. Por definición, los pacientes con gammapatía monoclonal de significado
Núria Serra, Carme Facundo, Cristina Canal, Yolanda Arce, Nadia Ayasreh, Anna Vila, Beatriz Bardají, Irene Silva, Víctor López, Silvia Benito, Jose Ballarín, Lluís Guirado   +11 more
doaj   +1 more source

Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin‐degrading enzyme, a new molecular vulnerability in multiple myeloma

British Journal of Pharmacology, Volume 183, Issue 12, Page 3355-3376, June 2026.
Inhibitors of insulin‐degrading enzyme boost PI cytotoxicity through an increased sensitivity of proteasome to PI inhibitors, induction of ISR, DNA damage and Myc down‐regulation. They overcome PI resistance in vitro and induce tumour regression in vivo.
Laetitia Lesire, Rebecca Deprez‐Poulain, Damien Bosc, Florence Leroux, Valerie Landry, Sarah Ourabah, Morgane Tardy, Clara Maillard, Ronan Gealageas, Julie Dumont, Adrien Herledan, Sandrine Warenghem, Manon Cruette, Celine Lenglart, Alexandre Biela, Catherine Piveteau, Eva De Smedt, Catharina Muylaert, Wenguang Liang, Elvira Garcia De Paco, Elina Alaterre, Sara Ovejero, Nicolas Robert, Fabien Delahaye, Wei‐Jen Tang, Peter van Endert, Elke De Bruyne, Jérôme Moreaux, Benoit Deprez   +28 more
wiley   +1 more source

Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma [PDF]

, 2019
Almost all multiple myeloma (MM) cases have been demonstrated to be linked to earlier monoclonal gammopathy of undetermined significance (MGUS). Nevertheless, there are no identified characteristics in the diagnosis of MGUS that have been helpful in ...
Musolino C., Ventura-Spagnolo E., Innao V., Pugliese M., Allegra A., Gangemi S., Allegra A. G., Di Salvo E.   +7 more
core   +1 more source

Rate of MGUS Progression to Haematological Malignancies: A Systematic Review

European Journal of Haematology, Volume 116, Issue 6, Page 889-906, June 2026.
ABSTRACT Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic pre‐cancerous condition that precedes plasma cell dyscrasias, including multiple myeloma (MM). Current clinical guidelines report that MGUS's rate of malignant progression to haematological malignancy (HM) is ~1% per year; however, reported rates have varied widely ...
Stephen James Quinn, Chris Cardwell, Lesley Ann Anderson, Charlene McShane   +3 more
wiley   +1 more source

Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia

, 2016
Since the initial identification of patients with monoclonal elevation of gamma globulin and associated clinical symptoms in 1944 by Jan Waldenström, several new insights have been gained using a range of approaches.
Mailankody, Sham, Landgren, Ola, Landgren, Carl   +2 more
core   +1 more source

Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025

European Journal of Haematology, Volume 116, Issue 6, Page 724-732, June 2026.
ABSTRACT Minimal residual disease (MRD) is a central biomarker in multiple myeloma (MM), offering unprecedented sensitivity for evaluating treatment efficacy and serving as a potential surrogate endpoint. We conducted a comprehensive analysis of clinical trials registered on ClinicalTrials.gov between 2014 and 2025.
Mimi Choon‐Quinones, George Dennis Obeng, Benjamin Asiedu‐Ayeh, Sampson Kawuo, Asmau Mohammed Tukur, Inusah Mohammed, Akosua Pokuaah Obeng, Jean‐Luc Harousseau, Anja Seckinger, Dirk Hose, Emmanuel Sarkodie, Attila Imre, Marcell Csanádi   +12 more
wiley   +1 more source

[Monoclonal gammopathies of undetermined significance].

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2009
Monoclonal gammopathy of undetermined significance (MGUS) is the most common type of monoclonal gammopathies. Genetic changes, various cytokines and bone marrow angiogenesis play an important role in the pathogenesis. As far as the malignant transformation of MGUS is concerned, size and type of the serum M-protein, serum kappa and lambda free light ...
V, Krizalkovicová, V, Maisnar, L, Pour, J, Radocha, R, Hájek   +4 more
openaire   +1 more source